Natera's Signatera Shows Superior Performance in Lymphoma Detection at ASH 2025
核心洞察
Natera's Signatera (搜索) circulating tumor DNA (搜索) test demonstrated superior performance compared to imaging in detecting lymphoma (搜索) recurrence in the largest real-world dataset across lymphoma subtypes.
The retrospective study of 144 patients showed that personalized ctDNA (搜索) detection at end-of-treatment and on-treatment clearance were strong predictors of clinical outcomes across multiple lymphoma (搜索) subtypes.
Signatera (搜索) helped clarify ambiguous imaging results and provided important insights for disease management, supporting its use as a response assessment tool in lymphoma (搜索) care.
Natera's personalized circulating tumor DNA (搜索) (ctDNA (搜索)) test Signatera (搜索) has demonstrated superior performance compared to standard imaging methods in detecting lymphoma (搜索) recurrence, according to new data being presented at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
Real-World Evidence Across Lymphoma Subtypes
The company announced results from the largest real-world dataset of personalized ctDNA (搜索) across lymphoma (搜索) subtypes, evaluating 144 patients across the spectrum of aggressive and indolent lymphomas. The retrospective real-world cohort study suggests broad clinical applicability of Signatera (搜索) for treatment response monitoring and end-of-treatment response assessment.
Key findings from the study demonstrate that Signatera (搜索) detected recurrence prior to imaging and outperformed standard surveillance methods. The personalized ctDNA (搜索) detection at the end of treatment and on-treatment clearance were strong predictors of clinical outcomes across multiple lymphoma (搜索) subtypes treated with standard-of-care therapy, including CAR-T cell therapy.
Clinical Impact on Disease Management
The study revealed that end-of-treatment assessment with Signatera (搜索) helped to clarify ambiguous imaging results, providing important insights for disease management. This clinical dataset supports the use of Signatera as a response assessment tool in lymphoma (搜索), where ctDNA (搜索)-MRD was incorporated into the NCCN Guidelines in January 2025 for patients with diffuse large B-cell lymphoma (搜索).
"The Signatera (搜索) data at ASH highlights our commitment to advancing precision oncology for patients with blood cancers," said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer at Natera. "The findings from our real-world data reinforce the value Signatera can offer to lymphoma (搜索) patients for personalized and precise care."
ASH 2025 Presentations
Natera and its collaborators will present four abstracts highlighting the clinical validity and utility of Signatera (搜索) in hematologic malignancies during the December 6-9, 2025 meeting. The presentations include studies on risk stratification across lymphoma (搜索) subtypes, measurable residual disease monitoring in multiple myeloma (搜索) following autologous hematopoietic cell transplant, whole-genome sequencing-based ctDNA (搜索) monitoring in diffuse large B-cell lymphoma (搜索), and molecular subtyping methods for DLBCL using whole-exome sequencing.
The oral presentation on December 6 at 2:45 PM ET will be delivered by Natalie Galanina, M.D., focusing on the real-world evaluation of ctDNA (搜索) for risk stratification across the spectrum of both aggressive and indolent lymphomas. Additional presentations will cover pilot studies in multiple myeloma (搜索) and novel molecular approaches for DLBCL characterization.